Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Official Title

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Keywords

Cancer, Rollover, pan-tumor, Leucovorin, Bevacizumab, Pembrolizumab, Nivolumab, Ipilimumab, Relatlimab, Sunitinib, Capecitabine, Oxaliplatin, Fluorouracil, Pemetrexed, Temozolomide, Daratumumab, Trametinib, Rucaparib, Cabozantinib, Nivolumab + Relatlimab, Regorafinib, Enzalutamide, B1: Nivolumab + Ipilimumab, B2: Nivolumab + Ipilimumab + Cabozantinib, B3: Nivolumab + Ipilimumab + Trametinib, C5: Relatlimab + Nivolumab + Ipilimumab, C6: Relatlimab + Nivolumab + Capecitabine, C9: Relatlimab + Nivolumab SAV + Bevacizumab, D1: Nivolumab + Temozolomide, D2: Nivolumab + Rucaparib, D3: Nivolumab + Daratumumab, D4: Nivolumab + Bevacizumab, E1: Bevacizumab Monotherapy, E2: Regorafinib Monotherapy, E4: Leucovorin + Oxaliplatin + Fluorouracil, E5: Enzalutamide Monotherapy, E6: Sunitinib Monotherapy, E7: Rucaparib Monotherapy, E8: Capecitabine Monotherapy, E9: Cabozantinib Monotherapy, E10: Pemetrexed Monotherapy, E11: Pembrolizumab Monotherapy, E3: Leucovorin + Fluorouracil

Eligibility

Locations

  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Center accepting new patients
    San Francisco California 94143 United States
  • Local Institution withdrawn
    San Francisco California 94115 United States
  • Huntsman Cancer Institute accepting new patients
    Salt Lake City Utah 84112-5550 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT03899155
Phase
Phase 2 Cancer, General Research Study
Study Type
Interventional
Participants
Expecting 1500 study participants
Last Updated